Evaluation of the Aptima™ transcription-mediated amplification assay (Hologic®) for detecting SARS-CoV-2 in clinical specimens
Résumé
Background:The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which appeared inlate 2019, has been limited by isolating infected individuals. However, identifying such individuals requiresaccurate diagnostic tools.Objective:This study evaluates the capacity of the Aptima™Transcription-Mediated Amplification (TMA) assay(Hologic®Panther System) to detect the virus in clinical samples.Study design:We compared the Aptima™assay to two in-house real-time RT-PCR techniques, one running on thePanther Fusion™module and the other on the MagNA Pure 96 and Light-Cycler 480 instruments. We included atotal of 200 respiratory specimens: 100 tested prospectively and 100 retrospectively (25 -ve/75 +ve).Results:Thefinal Cohen’s kappa coefficients were:κ= 0.978 between the Aptima™and Panther Fusion™assays,κ= 0.945 between the Aptima™and MagNA/LC480 assays andκ= 0.956 between the MagNA/LC480 andPanther Fusion™assays.Conclusion:Thesefindings indicate that the Aptima™SARS-CoV-2 TMA assay data agree well with those ob-tained with our routine methods and that this assay can be used to diagnose coronavirus disease 2019 (COVID-19).
Domaines
Maladies infectieusesOrigine | Fichiers produits par l'(les) auteur(s) |
---|